- Vagus Nerve Stimulation (VNS), a neuromodulation therapy involving electrical impulses to the vagus nerve, is gaining prominence in Europe as a non-pharmacological treatment for conditions such as epilepsy, depression, and cluster headaches. Its application is expanding due to rising neurological disorder prevalence and growing acceptance of implantable medical devices
- The growing demand for VNS devices in Europe is primarily driven by the increasing incidence of drug-resistant epilepsy, greater awareness about neuromodulation therapies, and continuous advancements in minimally invasive neurostimulation technologies. Additionally, the supportive reimbursement policies and rising healthcare investments across major EU nations are fueling adoption
- Germany dominated the Europe vagus nerve stimulation market with the largest revenue share of 28.7% in 2024, attributed to a well-developed neurology care network, high healthcare spending, and strong demand for implantable medical technologies. The country's focus on personalized medicine and its proactive stance toward integrating innovative neuromodulation therapies contribute significantly to market expansion
- France is anticipated to witness the highest CAGR in the European vagus nerve stimulation market during the forecast period. This growth is fueled by increasing awareness of non-drug treatment options for neurological conditions and government support for neurotechnology research. The presence of academic institutions and hospitals participating in VNS-related clinical studies is further driving adoption
- The implantable VNS devices segment accounted for the largest revenue share of 64.3% in 2024, owing to their established clinical efficacy in managing treatment-resistant epilepsy and depression. These devices are preferred in hospital environments for chronic neurological care
